

RNATICS Announces Distinguished Advisory Board

Munich, 15 November 2023 – RNATICS GmbH, a young, innovative biotech company focused on targeted nucleic acid therapies for inflammatory lung diseases, is pleased to announce the formation of its Advisory Board. We are proud to welcome four highly respected experts and leaders in the field. The addition of these esteemed individuals to the team marks a significant milestone in the company's growth and commitment to bringing transformative RNA therapies to patients.

The newly appointed Advisory Board members bring a wealth of experience and expertise to RNATICS. The board members have made landmark contributions to nucleic acid science and the life sciences industry, particularly in the field of nucleic acid therapies. Their guidance and insights will be invaluable as the company continues to develop breakthrough RNA therapies to treat inflammatory lung diseases.

Introducing the Advisory Board Members:

- 1) Prof. Thomas Tuschl: With a scientific career spanning over 30 years, Prof. Tuschl is a world-renowned authority in the field of small non-coding RNA and currently professor for RNA Molecular Biology at The Rockefeller University in New York, USA. His contributions have led to groundbreaking discoveries and understanding of the regulatory function of non-coding RNAs. Prof. Tuschl's expertise and experience will undoubtedly guide RNATICS towards pioneering innovations in novel RNA therapies.
- 2) Roger Hajjar, MD: A distinguished academic and translational researcher, Dr. Hajjar is currently the Head of the Mass General Brigham Gene and Cell Therapy Institute in Boston, USA. He is an internationally recognised scientific leader in the field of gene therapy and has made significant advances in the translation of gene therapies into human application. Dr. Hajjar's wealth of knowledge will support RNATICS in its mission to translate scientific excellence to patients.
- 3) Prof. Horst Domdey: A visionary networker and seasoned executive with an exceptional track record in shaping the biotech ecosystem in Germany, Prof. Domdey has successfully guided numerous biotech start-ups from academic spin-out to successful, independent companies. His strategic insights will help RNATICS navigate the complexities of the market as it develops into a clinical-stage company.

- 4) Dr. Ulrich Granzer: A regulatory thought leader in bringing nucleic acid therapies into clinical development, Dr. Granzer has an extensive background in regulatory submissions to both the European and US health authorities. He founded one of the leading regulatory consulting firms responsible for the majority of regulatory submissions for nucleic acid therapies (phase I to marketing approval). His leadership and advocacy for RNA therapies aligns with RNATICS' mission to establish RNA therapies as a successful modality in the treatment of inflammatory lung diseases.

The Advisory Board will play a pivotal role in guiding RNATICS' strategic decisions in the clinical development of its lead compound, fostering innovation in the development of novel RNA therapeutics, and providing critical insights as the company continues to advance its research and development efforts in this exciting and promising field.

"We are delighted to welcome these accomplished individuals to our Advisory Board," said Johannes Schmidt, PhD, CEO of RNATICS. "Their collective experience and dedication to the biotechnology industry, particularly nucleic acid therapeutics, will be instrumental in advancing RNATICS' mission to develop innovative therapies that improve human health and well-being."

The appointment of the Advisory Board members underscores RNATICS' commitment to excellence in its pursuit of breakthrough RNA therapeutic solutions. The company looks forward to a productive and innovative collaboration with its distinguished advisors.

For more information about RNATICS GmbH and its Advisory Board, please visit www.rnatitics.com.

About RNATICS:

RNATICS GmbH is a young, innovative biotech company developing targeted nucleic acid therapies for the inhalation treatment of inflammatory lung diseases. The drugs are selectively delivered to lung macrophages, specific immune cells in the lung, targeting disease-causing regulatory RNAs.

The most advanced drug candidate, RCS-21, is currently in development for the treatment of patients with acute respiratory hyperinflammation, such as bronchiolitis obliterans or viral infections. RNATICS plans after accomplishing mandatory toxicology investigation a first-in-human phase I clinical trial to start in 2024.

In addition, novel treatments based on this targeting technology are being actively developed pre-clinically for chronic inflammatory lung diseases, such as COPD and lung cancer.

Contact:

Dr. Johannes Schmidt
Chief Executive Officer
RNATICS GmbH
Am Klopferspitz 19a
D-82152 Martinsried/Planegg
info@rnatics.com // www.rnatics.com

Except for statements of historical fact, the information contained in this press release constitutes forward-looking statements and includes, but is not limited to, the (i) the expected development of the Company's business and projects; (ii) execution of the Company's vision and growth strategy; (iii) completion of the Company's projects that are currently underway, in development or otherwise under consideration.

Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable laws. The reader is cautioned not to place undue reliance on forward-looking statements.